Baseline symptom severity and efficacy of Silexan in patients with anxiety disorders : A symptom-based, patient-level analysis of randomized, placebo-controlled trials
The influence of baseline severity on the efficacy of Silexan, a proprietary essential oil from Lavandula angustifolia, in anxiety disorders has not been investigated in a pooled dataset. We report on an individual patient data analysis of all five double-blind, randomized, placebo-controlled trials with Silexan in anxiety disorders. Eligible participants received Silexan 80 mg/d or placebo for 10 weeks. Analyses were based on the Hamilton Anxiety Rating Scale (HAMA), its psychic and somatic anxiety subscores, and the Clinical Global Impressions (CGI) scale. To correlate baseline severity with outcome, patients were segregated into mild, moderate, and severe cases. Altogether 1,172 patients (Silexan, n = 587; placebo, n = 585) were analyzed. For the HAMA total score, we found a significant association between the score at baseline and the treatment effect of Silexan versus placebo at week 10 (p < 0.001). HAMA items from the somatic domain scored lower at baseline and showed less improvement than items from the psychic domain, particularly in patients with mild or moderate baseline symptoms. For CGI item 2 (global improvement), significant efficacy favoring Silexan were observed in mild, moderate, and severe baseline symptom severity. Although significant improvements were found for all subsets, the more severe the initial symptoms, the greater the treatment effects documented by the HAMA. Overall this analysis confirms that Silexan is an effective treatment option in early or mild stages of anxiety disorder. Given its favorable safety profile, Silexan can thus fill a therapeutic gap in the treatment of (subsyndromal) anxiety disorders.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:67 |
|---|---|
| Enthalten in: |
European psychiatry : the journal of the Association of European Psychiatrists - 67(2024), 1 vom: 01. März, Seite e23 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dold, Markus [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Anxiety Agents |
|---|
| Anmerkungen: |
Date Completed 20.03.2024 Date Revised 29.03.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1192/j.eurpsy.2024.16 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369151011 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369151011 | ||
| 003 | DE-627 | ||
| 005 | 20240330001058.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240301s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1192/j.eurpsy.2024.16 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1355.xml |
| 035 | |a (DE-627)NLM369151011 | ||
| 035 | |a (NLM)38425206 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dold, Markus |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Baseline symptom severity and efficacy of Silexan in patients with anxiety disorders |b A symptom-based, patient-level analysis of randomized, placebo-controlled trials |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.03.2024 | ||
| 500 | |a Date Revised 29.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The influence of baseline severity on the efficacy of Silexan, a proprietary essential oil from Lavandula angustifolia, in anxiety disorders has not been investigated in a pooled dataset. We report on an individual patient data analysis of all five double-blind, randomized, placebo-controlled trials with Silexan in anxiety disorders. Eligible participants received Silexan 80 mg/d or placebo for 10 weeks. Analyses were based on the Hamilton Anxiety Rating Scale (HAMA), its psychic and somatic anxiety subscores, and the Clinical Global Impressions (CGI) scale. To correlate baseline severity with outcome, patients were segregated into mild, moderate, and severe cases. Altogether 1,172 patients (Silexan, n = 587; placebo, n = 585) were analyzed. For the HAMA total score, we found a significant association between the score at baseline and the treatment effect of Silexan versus placebo at week 10 (p < 0.001). HAMA items from the somatic domain scored lower at baseline and showed less improvement than items from the psychic domain, particularly in patients with mild or moderate baseline symptoms. For CGI item 2 (global improvement), significant efficacy favoring Silexan were observed in mild, moderate, and severe baseline symptom severity. Although significant improvements were found for all subsets, the more severe the initial symptoms, the greater the treatment effects documented by the HAMA. Overall this analysis confirms that Silexan is an effective treatment option in early or mild stages of anxiety disorder. Given its favorable safety profile, Silexan can thus fill a therapeutic gap in the treatment of (subsyndromal) anxiety disorders | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Silexan | |
| 650 | 4 | |a anxiety disorders | |
| 650 | 4 | |a efficacy | |
| 650 | 4 | |a lavender | |
| 650 | 4 | |a severity of illness | |
| 650 | 7 | |a lavender oil |2 NLM | |
| 650 | 7 | |a ZBP1YXW0H8 |2 NLM | |
| 650 | 7 | |a Anti-Anxiety Agents |2 NLM | |
| 650 | 7 | |a Plant Oils |2 NLM | |
| 650 | 7 | |a Oils, Volatile |2 NLM | |
| 700 | 1 | |a Möller, Hans-Jürgen |e verfasserin |4 aut | |
| 700 | 1 | |a Volz, Hans-Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Seifritz, Erich |e verfasserin |4 aut | |
| 700 | 1 | |a Schläfke, Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a Bartova, Lucie |e verfasserin |4 aut | |
| 700 | 1 | |a Kasper, Siegfried |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European psychiatry : the journal of the Association of European Psychiatrists |d 1995 |g 67(2024), 1 vom: 01. März, Seite e23 |w (DE-627)NLM090678567 |x 1778-3585 |7 nnns |
| 773 | 1 | 8 | |g volume:67 |g year:2024 |g number:1 |g day:01 |g month:03 |g pages:e23 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1192/j.eurpsy.2024.16 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 67 |j 2024 |e 1 |b 01 |c 03 |h e23 | ||